Is There an Effect of Glucose Lowering Treatment on Incidence and Prognosis of Tuberculosis? A Systematic Review
- 362 Downloads
The association between diabetes and incidence of tuberculosis is well established, and observational studies have shown poor treatment outcome in tuberculosis related to hyperglycemia. The WHO recommends screening for diabetes among all patients with tuberculosis and optimized glycemic control aiming at improving tuberculosis outcome. However, no intervention studies support this notion. Patients with tuberculosis are often vulnerable with high degree of comorbidity, and, therefore, at high risk of adverse effects of intensive glucose control. Controlled intervention studies of the effect of glucose lowering treatment on tuberculosis outcomes are clearly warranted to justify screening for- and tight control of diabetes.
KeywordsDiabetes Glycemic control Tuberculosis incidence Tuberculosis outcome Glucose lowering treatment
Compliance with Ethics Guidelines
Conflict of Interest
Marit Eika Jørgensen is employed by Steno Diabetes Center, a research hospital working in the Danish National Health Service and owned by Novo Nordisk A/S.
Daniel Faurholt-Jepsen declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.••Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9:737–46. The study reviews the knowledge about the co-existence of diabetes and tuberculosis and potential mechanisms underlying the bidirectional association.PubMedCentralPubMedCrossRefGoogle Scholar
- 4.••WHO, International Union Against TB Lung Disease. Collaborative framework for care and control of tuberculosis and diabetes. 2011. Available at: http://www.who.int/diabetes/publications/tb_diabetes2011/en/index.html (accessed 28 Dec 2011). This WHO paper provides a statement on bidirectional management of diabetes in tuberculosis patients and vice versa.
- 5.•Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343. doi: 10.1136/bmj.d6898. The meta-analysis document both health benefits and adverse risks associated with intensive glycemic control of diabetes.
- 6.•Marais BJ, Lönnroth K, Lawn SD, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis. 2013;13:436–48. The paper focuses on synergies, and challenges of integration of tuberculosis care with management strategies for noncommunicable and communicable diseases.PubMedCrossRefGoogle Scholar
- 18.Syed Suleiman SA, Ishaq Aweis DM, Mohamed AJ, et al. Role of diabetes in the prognosis and therapeutic outcome of tuberculosis. Int J Endocrinol. 2012;2012. doi: 10.1155/2012/645362.
- 21.Kang YA, Kim SY, Jo K-W, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respir Int Rev Thorac Dis. [Published Online First: May 8, 2013]. doi: 10.1159/000348374.
- 24.Nandakumar N, Duraisamy K, Balakrishnan S, et al. Outcome of tuberculosis treatment in patients with diabetes mellitus treated in the Revised National Tuberculosis Control Programme in Malappuram District, Kerala, India. PLoS One. 2013;8:e76275. doi: 10.1371/journal.pone.0076275.
- 26.Reed GW, Choi H, Lee SY, et al. Impact of diabetes and smoking on mortality in tuberculosis. PLoS One. 2013;8:e58044. doi: 10.1371/journal.pone.0058044.
- 27.Reis-Santos B, Locatelli R, Horta BL, et al. Socio-demographic and clinical differences in subjects with tuberculosis with and without diabetes mellitus in Brazil—a multivariate analysis. PLoS One. 2013;8:e62604. doi: 10.1371/journal.pone.0062604.
- 29.Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One. 2013;8:e82943. doi: 10.1371/journal.pone.0082943.
- 30.Wang CS, Yang CJ, Chen HC, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect. 2009;137:203–10.Google Scholar
- 35.Banu Rekha VV, Balasubramanian R, Swaminathan S, et al. Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: an analysis of risk factors. Indian J Med Res. 2007;126:452–8.PubMedGoogle Scholar
- 40.Patel J, De Souza C, Jigjini S. Diabetes and tuberculosis. Ind J Tub. 1977;24:155–8.Google Scholar
- 42.Saxagliptin and tuberculosis. Prescrire Int. 2013;22:17.Google Scholar
- 43.Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. Accessed on 26 Feb 2014. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006739.pub2/abstract.
- 44.WHO: Treatment of Tuberculosis: Guidelines for National Programmes. 2009. Accessed 1 Mar 2010. http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html.
- 58.Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomized trial. Lancet. 2011;378:156–67.PubMedCentralPubMedCrossRefGoogle Scholar
- 61.IDF. IDF diabetes atlas. 6th ed. Brussels: International Diabetes Federation; 2013.Google Scholar